Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like they have re-negotiated the share purchase agreement just prior to a potential change in valuation. Leverage to continue moving forward without having to give away value, as our stock price is substantially undervalued.
I consider this another positive development in the course of 2-73's march towards approval. Freeing up capitol for trials, and other expenses, such as manufacture. Now, if the news comes out positively, and stock price increases significantly, the company can begin to tap the ATM with minimal dilutive effect.
Go Dr Missling.
Good time to update our prospectus, I like the table:)
https://ih.advfn.com/p.php?pid=nmona&article=82786595
AV1066 for Pain,
Thanks, I have been around for the last 6 years, and I had not seen that poster.
Possible that 1066 will go forward and maybe get approved under voucher?
-pine
Thanks jimmy, looking over the old poster it took me in another direction. Pain involved in PD. Makes me wonder, if we are able to restore Dopamine with 2-73, could it affect pain pathology?
Could of swore a 20k block went off before1600
Anavex 2-73 help with this?
"Fifteen children, many of whom had the coronavirus, have recently been hospitalized in New York City with a mysterious syndrome that doctors do not yet fully understand but that has also been reported in several European countries, health officials announced Monday night.
Many of the children, ages 2 to 15, have shown symptoms associated with toxic shock or Kawasaki disease, a rare illness in children that involves inflammation of the blood vessels, including coronary arteries, the city’s health department said"
https://www.chicagotribune.com/coronavirus/ct-nw-nyt-coronavirus-mysterious-illness-20200505-3qzdfngtmzelrlfs7on2pmt4le-story.html
Volume
500 shares at 3.45
total AH 10,747
Yes, in like Flynn, password good to go
Awesome, thanks
Dear Anavex,
Due to the unusual nature of quarantining in place.
Please consider an open Annual shareholder meeting with the ability to ask questions during the presentation, like a web-conference.
Thank you for your consideration.
Shareholder since 2015.
Length of pandemic
Recently read on Twitter feed. Viral load between day 10 and 20 drops dramatically. No Reinfection of Regis monkeys whether mild or severe symptoms. Virus does not transfer very well at temperatures above 68 degrees.
I would think that the virus would have a hard time surviving beyond June as society takes precautions to prevent spread. IMHO.
Do you track any other stocks? I have been researching Anavex, it looks like the real deal. AVXL.
Sorry i didn't catch your research. I asked two friends that have worked at Intel and they said it wouldn't work; but it does sound compelling
Ah thanks. Been watching for yrs promising but not able to drive sales...yet
Anyone have an idea as to why we are seeing the volume spike? Have not looked at the CC, he mist have mentioned something good, maybe just cash flow positive this yr?
Thanks makemydaze, that does tie in perfectly.
https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/202601/
Blarcamesine, spell check.
Bio conference today
https://www.veracast.com/webcasts/bio/ceoinvestor2020/63112233331.cfm#/player/html5/speed/a8
Note 14:19 min Dr Missling: "Progressive and reversible disease" (Alzheimer's)
I think that's the first time he has described Alzheimer's as reversible.
That sounds kind of big.
Good morning, your are correct, I have no MS, M.D. or PHD. I was just questioning the method of the trial. The lack of cognitive biomarkers used is very troubling. I don't have articles to site, just information I have read over the course of yrs. No need to listen to me I know nothing, just call me Schultz. But don't you think that maybe the result of Alzheimer's is causing fliments to become damaged, not the other way around? Maybe something up stream is causing the damage, like a mis-folded protein or a genetic mutation like an Apoe4. What 95% of AD is caused by SAD, sporadic Alzheimer's disease, looking at just the filament seems a little narrow, and how does a genetic mutation figure into the hypothesis? The filament hypothesis kind of falls apart there doesn't it? I really know less than you, but I ha9ve to critically think to stay ahead of the debt collectors. And I am trying to make decisions that add to my net worth. Good luck on your investment I'll pass.
Thanks got it. Phone is dying.
Hmm do you have a link to the 2017 article?
Reducing biomarkers, is kind of like picking a scab off of an injury and expecting the injury to be fixed, the company should be looking upstream to the root cause of the problem and the rest of the biomarkers, including the a beta, will reduce naturally. The paradox for them is why is the A beta increasing? (You have to look at the presentation to see that info) They list 10 yrs of research on biomarkers, but they leave out one of the Biggest A beta that goes in the wrong direction. Guess that didn't fit their narrative.
Sorry on my phone so it's hard to do citations. If you go to the PR on CTAD in Dec they have a link to the downloadable link. There I read over the inclusuonary criteria, where the age range is 55 to 85 and MMSE scoring range at baseline. They state in the presentation that they did not use MMSE (which is a commonly used Alzheimer's test) mini mental stae exam score as a primary indicator for their trial. The FDA has stated that cognition is a must before approval, so you would presume that the company would design a test that not only looks at biomarker reduction but also a stabilization of cognitive ability, or stability in the other commonly used test Activities of Daily living (ADL). This poor design shows how little they know about their drug and that they are not testing to a high standard. If i was advising someone about this company i would stear clear and look for a company with better science.
Just a quick look at the CTAD presentation A beta went up... other csf markers went down. They defined ALZ patients with MMSE yet they didn't look at the MMSE as a measure of cognitive change at the end of the study. This has P&D written all over it.
GLTY if you buy in, it will never get approved.